6/26/2025

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both general medicine and specialty disease areas. Management highlighted strong double-digit growth from 14 medicines, including continued momentum in cardiovascular, bone health, and biosimilars. CEO Robert Bradway attributed the performance to “growing patient demand for our innovative medicines” and called out the breadth of the company’s pipeline progress, including multi

Source: Yahoo

6/26/2025

Source: SeekingAlpha

6/26/2025

Source: SeekingAlpha

6/25/2025

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.

Source: Yahoo

6/25/2025

Keurig Dr Pepper Inc. (NASDAQ:KDP) is one of the 12 stocks on Jim Cramer’s radar recently. A caller asked if the company would be able to compete with Coca-Cola long term despite its “high debt”. In response, Cramer said: “Yeah, no, I don’t want to touch that one. I think if you want to be […]

Source: Yahoo

6/25/2025

Amgen Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

6/25/2025

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Source: Yahoo

6/25/2025

Key Insights Given the large stake in the stock by institutions, Amgen's stock price might be vulnerable to their...

Source: Yahoo

6/25/2025

Source: SeekingAlpha

6/24/2025

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a fourth straight day on Monday, dropping 5.84 percent to close at $272.44 apiece as investors sold off positions despite positive results from its weight loss drug trial, after Novo Nordisk—maker of the blockbuster Wegovy […]

Source: Yahoo

6/24/2025

Dow's nearly 600-point rally highlighted by gains in shares of Salesforce, American Express

Source: MarketWatch

6/24/2025

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss effects that weren’t as strong as previously reported.

Source: Yahoo

6/24/2025

These high-risk, high-reward small-cap biotech stocks deserve a second look.

Source: Yahoo

6/24/2025

Amgen Inc. (NASDAQ:AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ETCompany ParticipantsJustin Claeys - Vice President of Investor Relations...

Source: SeekingAlpha

6/23/2025

In the latest trading session, Amgen (AMGN) closed at $272.44, marking a -5.84% move from the previous day.

Source: Yahoo

6/23/2025

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.96%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.06%. September E-mini S&P futures (ESU25 ) are up +0.96%, and September E-mini Nasdaq futures...

Source: Yahoo

6/23/2025

At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.

Source: Yahoo

6/23/2025

Source: SeekingAlpha

6/23/2025

Presentation Operator MessageOperator My name is Julianne, and I will be your conference facilitator today for the Amgen Conference Call from the American Diabetes Association 85th Scientific

Source: Finnhub

6/23/2025

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with participants getting to the highest dose level through a three-step dose escalation. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Source: Yahoo